TO THE EDITOR
Resistance to Fas-mediated apoptosis is a characteristic of Hodgkin and Reed-Sternberg (HRS) cells, the malignant cell population in cHL. 1 The CD95/Fas (further on referred to as Fas) protein is a transmembrane death receptor, activation of which by its ligand FasL leads to initiation of a signaling cascade that terminates in apoptotic cell death. Several observations link Fas resistance to malignant transformation of HRS cells: Germinalcenter (GC) B cells, the precursor cells of HRS cells, are being stringently selected for expression of a high-affinity and non-selfreactive B-cell receptor (BCR). This selection process specifically involves activation of the Fas-signaling pathway. 2 Since HRS cells show crippling mutations (eg premature stop codons) in rearranged immunoglobulin genes leading to ablation of BCR expression in 25% of cases, and given the lack of BCR expression in virtually all cases, the HRS cell precursor cells apparently arise in the GC without undergoing antigenic selection, but rather escape Fas-mediated apoptosis. 1 Furthermore, in patients suffering from the inherited autoimmune lymphoproliferative syndrome (ALPS) -caused by heterozygous germline mutations of the TNFRSF6 gene encoding Fas -the risk for development of Hodgkin's lymphoma (HL) is increased 50-fold. 3 In contrast, the risk for development of non-Hodgkin's lymphoma (NHL) of various subtypes is increased 14-fold, suggesting that inactivation of Fas is particularly permissive for the development of HL. 3 Additionally, somatic TNFRSF6 gene mutations have been found in approximately 20% of GC or post-GC-derived B-cell NHL corroborating the view that Fas can act as a tumor suppressor in GC-derived lymphomas. 2 However, sequence analysis of the TNFRSF6 gene in primary HRS cells revealed destructive mutations in only B10% of the cases. 4 Taken together, these observations suggest that the evolving HRS cell clone may be selected for inactivation of the Fassignaling pathway in which somatic mutations of the TNFRSF6 gene play only a minor role.
We hypothesized that mutations in other genes involved in apoptotic signaling from cell-surface death receptors might be involved in apoptosis resistance in cHL. The proteins caspase-8, caspase-10 and FADD are recruited to the intracellular part of Fas upon activation where they constitute the death-inducing signaling complex (DISC). DISC formation is a critical event in the initiation of Fas-mediated death signals. The genes CASP8, CASP10 and FADD encoding the proteins caspase-8, caspase-10 and FADD were therefore chosen for this analysis. Additionally, mutations in the CASP10 gene have been identified as the underlying cause of another subtype of ALPS lacking TNFRSF6 mutations, termed ALPS type II. Moreover, somatic mutations in the CASP10 gene were recently found in about 15% of NHL, most of them being GC B-cell derived. 5 Thus, all coding exons of the CASP8, CASP10 and FADD genes were amplified, and directly sequenced from DNA of cHL cell lines L1236, L428, KM-H2 and L591 (Table 1) . To address the question whether single alleles of CASP8, CASP10 or FADD genes might be inactivated in cHL cell lines by large chromosomal deletions, we analyzed the sequences for the presence of known monoallelic single nucleotide polymorphisms (SNPs) indicated by 'double peaks' in the electropherograms (ie presence of wild-type and polymorphic allele). The detection of such double peaks in at least one exon of the CASP8 and CASP10 genes in all four cell lines analyzed indicates amplification of both alleles, excluding the possibility that single alleles of these genes might be affected by chromosomal deletions in these cases. In the case of FADD, heterozygous SNPs were only detected in KM-H2 and L591 cells. We can therefore not formally rule out inactivation of single FADD alleles by large deletions in L1236 and L428 cells. Further analyses of the sequences revealed lack of somatic CASP8, CASP10 and FADD gene mutations in all cell lines analyzed. Taken together, the HRS cell lines L1236, L428, KM-H2 and L591 lack somatic mutations or large chromosomal deletions of genes encoding the most important DISC members caspase-8, caspase-10 and FADD.
To further determine the role of mutations in the CASP8, CASP10 and FADD genes in the pathogenesis of cHL, we amplified and sequenced candidate exons of the CASP8, CASP10 and FADD genes from HRS cells that were microdissected from primary lymphoma biopsy specimens of ten cases of cHL by laser microdissection and pressure catapulting using a PALM microlaser device (PALM; Bernried, Germany). Characteristics of these cases are summarized in Table 1 . Owing to the single-cell PCR approach that has limited throughput capacity and since 11/17 gene mutations within CASP10 previously reported in B-cell NHL were located in exon 9, 5 this exon was chosen for analysis. Exon 9 is also functionally most informative since it encodes nearly the complete protease domain of the protein. Exons 8, 9 and 10 of the CASP8 gene were chosen because they encode the protease domain of caspase-8. Finally, the two coding exons of the FADD gene were selected for this analysis. Bidirectional sequences were obtained from 270 samples containing at least one microdissected HRS cell (in some cases up to 15 single HRS cells from an individual case were pooled in single reaction tubes; Table 1 ). At least three individual samples were analyzed per case and amplicon, except for exon 1 of FADD, where in three of ten cases only two samples could be analyzed, due to shortage of biopsy material. However, in each of these samples the presence of heterozygous SNPs excludes the presence of a mutant allele that might have been missed by the cell-isolation strategy used. Direct sequencing of CASP8, CASP10 and FADD genes revealed no somatic mutations in primary HRS cells in any of the 10 cases of cHL. Moreover, heterozygous SNPs were present in the sequences of at least one exon of the CASP8, CASP10 and FADD genes in 8/ 10, in 2/10 and in 7/10 cases, respectively (Table 1) . We therefore rule out large heterozygous deletions of these genes in most cases. Taken together, these results show that the CASP8, CASP10 and FADD genes are not affected by somatic mutations in a set of 10 primary cases of cHL.
To determine if altered expression of DISC proteins might play a role in apoptosis resistance in cHL, we performed Western blotting experiments with cell lysates prepared from L1236, L428, KM-H2 and L591 cHL cell lines. Only antibodies were used in these experiments for which specificity had previously been verified on lysates from cells overexpressing the respective genes (caspase-10: clone 4C1, 1:100, MBL, Nagoya, Japan; caspase-8: clone C15, 1:300, Transduction Laboratories, San Diego, CA, USA; FADD: clone 1, 1:250, Transduction Laboratories). All four cell lines expressed caspase-8, caspase-10 and FADD proteins except L428 cells that expressed very low levels of caspase-10 ( Figure 1 ). Attempts to investigate the expression of caspase-10 in primary cHL tissue failed because the antibody (4C1), for which specificity was confirmed using a cell line ectopically expressing caspase-10, consistently failed to produce a specific signal in control tissue, even when applying different methods of antigen retrieval or when cryopreserved tissue was used (data not shown). Another antibody yielded unspecific staining in control tissue specimens and HRS cells of 
Sequences were compared to RefSeq sequences NM_001228 (CASP8), NM_032977 (CASP10) and NM_003824 (FADD cHL specimens (data not shown) and was therefore also excluded for further analysis. We conclude that analysis of protein expression of caspase-10 in primary cHL biopsies is not feasible with these and other commercially available antibodies. Importantly, FADD and caspase-8 proteins were both recently shown to be expressed by primary HRS cells. 6 Here, we show that the CASP8, CASP10 and FADD genes, encoding important members of the DISC of cell-surface death receptors, are not affected by somatic mutations or large chromosomal deletions in a total of 14 cases of cHL. These findings suggest that genetic inactivation of these genes does not play a dominant role in rendering HRS cells apoptosis-resistant and therefore are not involved in malignant transformation in cHL.
For the sequence analysis of DISC members in primary HRS cells, we selected exons 8, 9 and 10 of the CASP8 gene, exon 9 of the CASP10 gene and both coding exons of the FADD gene, encoding the protease domains of both caspases and the entire FADD protein. Since the DISC is composed of multiple monomers of the respective proteins, heterozygous mutations located within these regions of the caspase genes will likely lead to recruitment of proteins encoded by the wildtype and the mutated allele into the signaling complex. The functional consequences of such a mutation that does not impair assembly, but that prevents signal transduction of the DISC, are considered to be most severe and such dominantly negative acting mutations might therefore be selected for. The observation that most somatic mutations in the TNFRSF6 gene that have been reported in B cell malignancies are located in the intracellular death domain argues in favor of this hypothesis. 2, 4 Moreover, such a dominant-negative effect of heterozygous TNFRSF6 gene mutations has been shown experimentally. Finally, heterozygous mutations in the CASP10 gene are mostly located in exon 9, encoding the protease domain, and these mutations occur somatically in B cell lymphomas and as germline mutations in ALPS type II patients. 5 Thus, the exons analyzed by us cover the most relevant ones for a mutation screen of the CASP8, CASP10 and FADD genes. This analysis, however, revealed that these genes were unmutated in all 14 cases of cHL investigated.
We recently demonstrated constitutive expression of the apoptosis inhibitor c-FLIP by cultured and primary HRS cells. 7 In two later studies, the functional significance of c-FLIP expression in cHL has been investigated in detail. 6, 8 These analyses show that constitutive expression of c-FLIP contributes to the Fas-resistant phenotype of HRS cells. Given the low frequency of gene mutations affecting genes involved in signaling from death receptors (TNFRSF6, CASP8, CASP10 and FADD genes) and the high expression of the antiapoptotic protein c-FLIP in cHL, we suggest that resistance to deathreceptor-mediated apoptosis is a result of dysregulated expression of apoptosis-related genes, such as c-FLIP, rather than mutational inactivation of genes involved in apoptosis signaling. Importantly, the gene encoding c-FLIP is regulated by the transcription factor NF-kB. Since NF-kB is constitutively active in cHL, it is conceivable that an antiapoptotic gene expression program driven by the dysregulated transcriptional activity of NF-kB is the likely cause of Fas-resistance in cHL. The HRS precursor cell in the process of malignant transformation may thus escape Fas-mediated negative selection in the GC, giving rise to the malignant clone. Another argument for this view comes from the observation that mutations in the NFKBIA gene encoding IkBa -an important negative regulator of NF-kBoccur in 10-30% of cHL cases. Importantly, it was found that in one cHL case (case 3 in Table 1 ), all individual HRS cells harbored a truncating NFKBIA mutation, while the TNFRSF6 gene exhibited two different mutations in two subclones. 4 Thus, mutations leading to inactivation of IkBa can be regarded as primary transforming events, leading to constitutive activation of NF-kB. Moreover, NF-kB activation may hence be regarded as the initial functional step in tumor initiation in cHL.
Taken together, we show that mutational inactivation of CASP8, CASP10 and FADD genes are unlikely to play an important role in the pathogenesis of cHL. It might therefore be speculated that activation of NF-kB may lead to functional inactivation of the Fas pathway through upregulation of c-FLIP, thereby enabling the precursor cell to evade negative selection in the GC and to lead to cHL.
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